CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
of Best Available Therapy (BAT) for treatment-resistant relapsing multiple sclerosis (MS). Participants will be randomized...
Phase 3
New York, New York, United States and 18 other locations
will evaluate the pharmacokinetics, safety and tolerability, and immunogenicity of ocrelizumab administered subcutaneously to participants with multiple...
Phase 1
New York, New York, United States and 20 other locations
In this study, researchers will learn more about a study drug called BIIB091 in participants with MS who may be experiencing relapses. It is...
Phase 2
Teaneck, New Jersey, United States and 76 other locations
To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in pediatric patients with multiple sclerosis (MS...
Phase 3
New Brunswick, New Jersey, United States and 107 other locations
(maintenance) in people with systemic lupus erythematosus (lupus), infantile spasms, adults with acute relapses or flares of multiple sclerosis...
Phase 2
Palisades Park, New Jersey, United States of America and 2 other locations
This study aims to examine the efficacy and safety of obexelimab in participants with relapsing multiple sclerosis...
Phase 2
Teaneck, New Jersey, United States of America and 19 other locations
This study will evaluate if relapsing-remitting MS patients that have not had a relapse in the past year would benefit from a switch to ofat...
Phase 4
Neptune, New Jersey, United States and 36 other locations
with fingolimod in children and adolescents with relapsing-remitting multiple sclerosis aged between 10 and \< 18 years over a dura...
Phase 3
New York, New York, United States and 121 other locations
Open-label study to evaluate the effectiveness of treatment with ofatumumab in subjects transitioning from any fumarate-based RMS approved therapy or...
Phase 3
Woodmere, New York, United States and 122 other locations
This study will evaluate the impact of ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) participants that are very early...
Phase 4
Hackensack, New Jersey, United States and 35 other locations
Clinical trials
Research sites
Resources
Legal